Healthcare

Neuren Pharmaceuticals Limited (ASX:NEU) develops treatments for serious neurological disorders affecting children and receives royalty income associated with DAYBUE, a treatment for Rett syndrome. In a May 2026 shareholder update, Neuren reported Q1 2026 royalty income of US$10.4 million, up 23% on the same …

AVITA Medical, Inc. develops and commercialises technologies used in acute wound care, including the RECELL platform for burns and trauma wounds Its published second-quarter 2026 results provide a view of product revenue, cash expenditure and the company’s commercial priorities ahead of the next reporting …

Aroa Biosurgery Limited manufactures and supplies regenerative tissue technologies for wound care and surgical applications. The company’s current operating picture includes recent clinical publications, product promotion arrangements and the FY27 guidance issued with its annual results.

Cogstate Limited provides cognitive assessment technologies and clinical-trial data services, particularly for studies involving the central nervous system. Its October business update described new sales contracts, committed future work and the timing of expected revenue recognition across research programs.

Fisher & Paykel Healthcare Corporation Limited designs and manufactures medical devices and systems for respiratory care, acute care and surgery. Its results for the financial year ended 31 March 2026 provide a recent financial view of hospital therapies, consumables and overall group profitability.

For the financial year ended 30 June 2026, CSL (ASX:CSL) reported total revenue of US$15.8 billion, a decline of 1% on the company’s comparative basis. Underlying net profit after tax and amortisation, or NPATA, was US$3.1 billion, down 2%. The company described FY26 as …

Quarterly revenue for Resmed Inc. (ASX:RMD) increased to $1,415 million from $1,336 million in the corresponding period, a reported rise of 6% year on year. On a core constant-currency basis, revenue increased 7%.